OmpL1 DNA vaccine cross-protects against heterologous Leptospira spp. challenge.

Simple item page
dc.contributor.authorManeewatch, Santien_US
dc.contributor.authorTapchaisri, Pramuanen_US
dc.contributor.authorSakolvaree, Yuwapornen_US
dc.contributor.authorKlaysing, Buppaen_US
dc.contributor.authorTongtawe, Pongsrien_US
dc.contributor.authorChaisri, Uraien_US
dc.contributor.authorSongserm, Thaweesaken_US
dc.contributor.authorWongratanacheewin, Surasakdien_US
dc.contributor.authorSrimanote, Potjaneeen_US
dc.contributor.authorChongsa-nguanz, Manasen_US
dc.contributor.authorChaicumpa, Wanpenen_US
dc.date.accessioned2009-05-27T17:17:02Z
dc.date.available2009-05-27T17:17:02Z
dc.date.issued2007-03-26en_US
dc.descriptionPublished by the Allergy and Immunology Society of Thailand.en_US
dc.description.abstractAvailable leptospirosis vaccines made up of inactivated bacteria or their membrane components elicit immunity which is serovar specific and unsatisfactory immunological memory. A vaccine that protects across Leptospira serogroups/serovars, i.e. broad spectrum, and induces long-lasting memory is needed for both human and veterinary uses. In this study, a plasmid DNA vaccine was constructed from cloning gene encoding a transmembrane porin protein, OmpL1, of pathogenic Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni into a mammalian expression vector pcDNA3.1(+). The protective efficacy of the ompL1-pcDNA3.1(+) plasmid DNA vaccine was studied by immunizing hamsters intramuscularly with three doses of the vaccine (100 microg per dose) at two week intervals. The empty pcDNA3.1(+) and PBS were used as mock as negative vaccine controls, respectively. All animals were challenged with the heterologous Leptospira interrogans, serogroup Pomona, serovar Pomona (10 LD50), at one week after the last vaccine booster. The ompL1-pcDNA3.1(+) plasmid DNA vaccine rescued some vaccinated animals from the lethal challenge and delayed death time, reduced morbidity, e.g. fever, and/or the numbers of Leptospira in the tissues of the vaccinated animals. While the results are encouraging, further studies are needed to optimize the immunization schedule, vaccine dosage and formulation in order to maximize the efficacy of the vaccine.en_US
dc.description.affiliationGraduate Program of Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University Rangsit Center, Pathum-thani 12121, Thailand.en_US
dc.identifier.citationManeewatch S, Tapchaisri P, Sakolvaree Y, Klaysing B, Tongtawe P, Chaisri U, Songserm T, Wongratanacheewin S, Srimanote P, Chongsa-nguanz M, Chaicumpa W. OmpL1 DNA vaccine cross-protects against heterologous Leptospira spp. challenge. Asian Pacific Journal of Allergy and Immunology. 2007 Mar; 25(1): 75-82en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/36853
dc.language.isoengen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBacterial Outer Membrane Proteins --immunologyen_US
dc.subject.meshBacterial Vaccines --administration & dosageen_US
dc.subject.meshCOS Cellsen_US
dc.subject.meshCercopithecus aethiopsen_US
dc.subject.meshCricetinaeen_US
dc.subject.meshCross Reactionsen_US
dc.subject.meshFemaleen_US
dc.subject.meshLeptospira interrogans serovar icterohaemorrhagiae --classificationen_US
dc.subject.meshLeptospirosis --immunologyen_US
dc.subject.meshMesocricetusen_US
dc.subject.meshPlasmidsen_US
dc.subject.meshVaccines, DNA --administration & dosageen_US
dc.titleOmpL1 DNA vaccine cross-protects against heterologous Leptospira spp. challenge.en_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Asian Pacific Journal of Allergy and Immunology